Clinical Trial Update: A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

Phase II/III trial evaluating the efficacy and safety of QL1706 in patients with nasopharyngeal carcinoma; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• QL1706

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Nasopharyngeal Carcinoma | Phase 2, Phase 3 | Status: UNKNOWN